Final Version 2.2 – NOW released for publication on Monday, July 22, 2013 at 7 am EDT
Bruker Announces AVANCE™-IVDr as a Standardized NMR Platform for Clinical Screening
and In Vitro Diagnostics (IVD) Discovery and Validation
New AVANCE-IVDr System Offers High Performance and Throughput for the Development and Validation of
Emerging High-Quality, Information-Rich and Cost-Effective IVD-by-NMR and Clinical Screening Assays
KARLSRUHE, Germany – July 22, 2013 – Bruker today announces a standardized nuclear magnetic resonance
(NMR) spectroscopy platform for its clinical and diagnostics partners that enables cost-effective, high-performance NMR
clinical screening and IVD-by-NMR discovery, development and validation of novel NMR assays.
The new AVANCE-IVDr system, presently for research use only, is a complete, proven and standardized
platform for NMR clinical research and screening, as well as for IVD-by-NMR research. It features high sensitivity and
information-rich output at 600 MHz proton-NMR frequency, and incorporates advanced hardware, software, automation,
spectral libraries and standard operating procedures (SOPs) for high-performance bio-fluid screening and assay validation.
Customer benefits include higher information content and spectral feature differentiation compared to low-field NMR
systems, as well as excellent reproducibility, high throughput and potentially dramatically lower cost per sample for better
clinical screening and IVD-by-NMR.
Dedicated to NMR-based clinical screening
and diagnostics, the AVANCE-IVDr is optimized for
ease-of-use and highest data quality and reliability. The
new standardized platform offers barcode analysis, control
by a LIMS system, the high-throughput, temperaturecontrolled autosampler SampleJet™, remote access, and
automatic analysis and customizable analytical results
reporting. Based on Bruker-validated SOPs, the
AVANCE-IVDr platform enables the development of
diagnostic tools for body-fluids, or even biopsy samples,
Surgeons with two new AVANCE-IVDr NMR systems at the
Imperial/St. Mary’s Clinical Phenome Center (London, UK)
that can address a variety of medical questions. The SOPs guarantee the production of highly reproducible clinical data,
enabling the exchange and validation of novel NMR assays between laboratories on a global basis. In a translational clinical
research environment the results produced by these NMR assays can easily be transferred into clinical screening and future
IVD use.
Bruker’s NMR spectroscopy systems are already in use in more than forty clinical research centers worldwide,
including hospitals working on modern health-related screening techniques, such as human metabonomics. The AVANCEIVDr system in its latest, standardized configuration has been installed already at several customer and strategic partner sites.
Cross calibrations performed by Bruker across several centers have demonstrated NMR’s unique advantage that spectra from
samples prepared and measured under the Bruker SOPs are identical, independent of a center`s location or operating staff.
As a result of a long-standing collaboration with Imperial College London, the AVANCE-IVDr platform is
already enabling the analysis of over 100,000 samples per year at the UK’s recently opened MRC-NIHR Phenome Centre.
This level of large-scale health-related NMR screening is paving the way for worldwide epidemiological studies as well as
for clinical research and diagnosis. The benefits have been significant: facilitated by the low cost per sample and the even
lower cost per parameter as compared to established single parameter screening methods, novel NMR methods for
determining the cause of disease, delivering individualized patient treatment and developing strategies for prevention are now
available to many clinical researchers.
Professor Jeremy Nicholson, Director of the MRC-NIHR Phenome Centre and Head of the Department of
Surgery and Cancer at Imperial College London, commented: “The latest generation of Bruker NMR instruments gives us
staggering day to day and long term reproducibility and reliability of spectral acquisition, coupled with the ability to do
automated digital quantification of multiple metabolites. Thus, uniquely, the NMR technology platform can be used in
simultaneous exploratory and targeted modes. We are totally committed to the use of NMR spectroscopy (in association with
mass spectrometry) as a definitive bio-screening tool, and the latest technology developments now allow the deployment of
the platform on an industrial scale.”
Dr. Manfred Spraul, Bruker’s Director of Applied NMR Business Development, added: “Migrating from
translational research to clinical diagnostics requires robust, identical instrumentation in research facilities and hospitals,
which is why Bruker has decided to offer the standardized AVANCE-IVDr platform, enabling a smooth transfer from health
research and large epidemiological studies, to our partners’ emerging IVD assays at the highest quality and reproducibility.
With modern NMR technology and the right SOPs, we and our collaborators have opened the path to complex mixture
analysis using push-button technology, establishing NMR as one of the two major technologies used in metabolic profiling
and screening.”
About Bruker Corporation
Bruker Corporation (NASDAQ: BRKR) is a leading provider of high performance scientific instruments and solutions for
molecular and materials research, as well as industrial, diagnostics and applied analysis.
For more information, please visit www.bruker.com
For more information on AVANCE-IVDr , please visit: www.bruker.com/AVANCE-IVDr
Media Contact:
Dr. Thorsten Thiel
Bruker Director of Marketing Communications
T: +49 (721) 5161 – 6500
E: thorsten.thiel@bruker.com